Astrazeneca Pharma India's Q1 FY25 Financial Report Shows Mixed Results

Astrazeneca Pharma India, a midcap pharmaceutical company, has recently announced its financial results for the quarter ending June 2024. The company’s stock has been given a ‘Hold’ call by MarketsMOJO.

According to the financial report, Astrazeneca Pharma India has seen a flat performance in the quarter, with a score of -1 compared to 3 in the previous quarter. However, there are some positive aspects to the company’s financials. The dividend per share (DPS) has been consistently growing over the past five years, with the highest DPS of Rs 24.00. The company has also shown a positive trend in net sales, with the highest recorded at Rs 387.52 crore in the last five quarters. Additionally, the profit after tax (PAT) has grown by 22.2% over the average PAT of the previous four quarters.

On the other hand, there are some areas of concern for Astrazeneca Pharma India. The operating cash flow has been consistently falling over the past three years, with the lowest recorded at Rs 27.87 crore. The profit before tax (PBT) has also shown a negative trend, with a fall of -19.1% over the average PBT of the previous four quarters. The company’s earnings per share (EPS) have also declined, with the lowest recorded at Rs -4.72 in the last five quarters. Furthermore, the debtors turnover ratio has slowed down, with the lowest recorded at 8.46 times in the last five half-yearly periods.

Overall, Astrazeneca Pharma India’s financial performance for the quarter ending June 2024 has been mixed, with some positive and negative aspects. Investors are advised to hold their positions and monitor the company’s performance closely.